Teva Pharmaceutical Industries Limited (OTCMKTS: TEVA) today announced the Ministry of Health, Labor, and Welfare (MHLW) had approved AJOVY injection for the preventive treatment of migraine in grownups in Japan.
AJOVY® designed for the deterrent cure of migraine
“In Japan is 8.4% of adults are yearly suffereing from migraine. Along with our associate, Teva we are able to offer persons living with migraine this biopharmaceutical cure with supple dosing options,” said Sven Dethlefs, Ph.D., Executive Vice President, International Markets Commercial Region, and Global Marketing and Portfolio at Teva.
Injection developed for Japanese markets by Otsuka Pharmaceutical Co., Ltd
Otsuka Pharmaceutical Co., Ltd. developed AJOVY® in Japan with the aid and collaboration of Teva as part of a May 2017 particular authorization contract. In 2020, the two companies announced consequences from two essential studies of AJOVY in people living with sporadic and long-lasting migraines in Japan. The trials attained the endpoints with scientific and statistical implications against placebo. Statistically significant enhancements versus placebo also were established for all ancillary endpoints. AJOVY was well borne with a similar contrary events outline compared to placebo.
Makoto Inoue, President and Representative Director of Otsuka Pharmaceutical, commented, “Patients with migraine not only agonize the pain of headaches, but also suffer a range of incapacitating indications impacting their daily exists. While expending the experience we have accrued to address the problems faced by patients, we hope to give sustenance to the lives of many patients by providing AJOVY as a novel treatment opportunity to those in need.”
Teva, who holds with Takeda a combined business undertaking in the Japanese market, emphasizes commercializing an assortment of multifaceted generics and forte assets to address the wide-ranging needs of patients and healthcare specialists in Japan.